SCHEDULE: FMR LLC Reports 6.2% Stake in Mirum Pharmaceuticals
Beneficial Ownership Filing (Schedule 13G)
FMR LLC has disclosed beneficial ownership of 6.2% of Mirum Pharmaceuticals Inc.'s common stock as of June 30, 2026.
Summary
- FMR LLC, along with Abigail P. Johnson and other affiliated entities, has filed a Schedule 13G.
- As of June 30, 2026, FMR LLC beneficially owns 3,777,851.04 shares of Mirum Pharmaceuticals Inc. common stock.
- This represents 6.2% of the class of securities.
- The filing indicates that FMR LLC has sole voting power and sole dispositive power over these shares.
- Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, and members of the Johnson family are predominant owners of FMR LLC's voting shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a routine Schedule 13G filing indicating a significant but not controlling stake by an institutional investor.
Positives
- FMR LLC, a significant institutional investor, holds a substantial stake in Mirum Pharmaceuticals, indicating confidence in the company's potential.
- The filing confirms a clear and defined ownership percentage (6.2%), providing transparency to the market.
Negatives
- The filing does not contain any negative financial or operational information as it is a disclosure of beneficial ownership.
- No specific negative commentary or concerns are raised within the document.
Risks
- The filing itself does not present risks; however, the concentration of ownership by a large institutional holder could influence market dynamics.
- Potential for future changes in FMR LLC's investment strategy could impact Mirum Pharmaceuticals' stock.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Mirum Pharmaceuticals' future performance.
Management Comments
- Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.
- Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.
- The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like FMR LLC when they acquire a significant stake (typically 5% or more) in a public company. This filing indicates FMR LLC's investment in the biotechnology or pharmaceutical sector, where Mirum Pharmaceuticals operates.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholders' Voting Agreement | Members of the Johnson family and other Series B shareholders of FMR LLC have entered into a voting agreement to vote Series B common shares according to the majority vote. | Not specified, but in effect as of the filing date. | Ensures coordinated voting power among key shareholders of FMR LLC, potentially influencing strategic decisions related to FMR LLC's investments. |
Stakeholder Impact
- Shareholders: Increased transparency regarding a significant institutional investor's stake, potentially influencing market perception and trading activity.
- Management of Mirum Pharmaceuticals: May need to engage with FMR LLC regarding strategic direction or governance matters.
- FMR LLC Shareholders: The investment in Mirum Pharmaceuticals contributes to the overall portfolio performance of FMR LLC.
Next Steps
- FMR LLC will continue to hold and potentially manage its investment in Mirum Pharmaceuticals.
- Mirum Pharmaceuticals will continue its business operations and reporting as usual.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/31/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 06/30/2026 | Date of Event Which Requires Filing of this Statement (Reporting period end). |
| 08/05/2026 | Date of joint filing of Schedule 13G. |
Keywords
Mirum Pharmaceuticals, FMR LLC, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Ownership Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.